Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 5


Oral and Poster Abstracts Oral 624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Frontline Clinical Trials Biological, Antibody Therapy, Lymphomas, Non-Biological, Chemotherapy, T Cell Lymphoma, Diseases, Therapies, Lymphoid Malignancies Steven M. Horwitz, MD1, Kerry J. Savage, MD, MSc, FRCPC2, Tim Illidge, MD, PhD3*,...

  • 123456 Profile photo of Madelyn

    In a 5 year follow up subgroup analysis of BV-CHP vs CHOP for PTCL, the AITL subgroup had no benefit of BV-CHP over CHOP, and in fact PFS favored CHOP. Recall, that this trial was specifically designed to be enriched for 75% ALCL which carried the treatment across subgroups. AITL remains an aggressive disease which requires more effective therapies.